Evidence map›Paper›PMID 35667975›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2022

Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.

Lisa A Carmody, Linda M Kalikin, Donald R VanDevanter, Gen Li, Kristopher Opron, Richard H Simon, Lindsay J Caverly, John J LiPuma

Open access · greenAbstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lisa A CarmodyDepartment of Pediatrics, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109, United States.
Linda M KalikinDepartment of Pediatrics, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109, United States.
Donald R VanDevanterDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Gen LiDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, United States.
Kristopher OpronDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Richard H SimonDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Lindsay J CaverlyDepartment of Pediatrics, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109, United States.
John J LiPumaDepartment of Pediatrics, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109, United States. Electronic address: jlipuma@umich.edu.
University of Michigan · USUniversity School · US

Funding

Dynamics of airway microbiota at pulmonary exacerbation in cystic fibrosisR01HL136647 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIPUMA, JOHN J · 2017 to 2020
$1.3M
Omics of pulmonary exacerbations in cystic fibrosisR56HL126754 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIPUMA, JOHN J · 2016 to 2016
$388k
NHLBI NIH HHS R01 HL136647NHLBI NIH HHS R56 HL126754
6 · The paper itself

Abstract

Chronic polymicrobial airway infections are a hallmark of cystic fibrosis (CF) lung disease. Antibiotic therapy is a primary treatment of CF pulmonary exacerbations (PEx); however, the impact of episodic antibiotic treatment on airway bacterial communities has not been well described. We analyzed sputum samples from adults with CF obtained immediately before and during antibiotic treatment of PEx. Sequencing of the V4 region of the bacterial 16S ribosomal RNA gene was used to assess changes in bacterial community structure during antibiotic treatment. The peak impact of antibiotic treatment was observed by day four or five of treatment. These findings advance our understanding of bacterial community dynamics during antibiotic treatment of PEx and complement recent and ongoing studies evaluating the optimal duration of antibiotic therapy for PEx.

Indexed as

Cystic FibrosisAdultAnti-Bacterial AgentsBacteriaHumansLungRNA, Ribosomal, 16SSputumAnti-Bacterial AgentsRNA, Ribosomal, 16SAirway infectionCystic fibrosis pulmonary exacerbationMicrobial community dynamicsMicrobiome

Identifiers

PMID35667975
PMCPMC10440828
OpenAlexW4281970443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.